Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by Duster340on Jan 20, 2023 11:50am

398 Views

Post# 35235662

Antibe RSU's Vesting (could be a bullish sign)

instead of taking cash managemnt is trading there rsu's for stock is this to reserve company cash or is it because they know the stock will be going a lot higher than 59 cents. i think it is the later. i do not recall what they did with there rsu's in 2022.

TORONTO, CANADA — (January 11, 2021)

Board of Directors Recognizes Significant Progress with RSU Grants

In view of the achievement of human proof-of-concept for otenaproxesul and commercial validation, the Board of Directors is awarding 2,092,000 restricted share units (“RSUs”) to directors, officers, employees and consultants pursuant to Antibe’s RSU plan. The vesting of 50% of the RSUs granted to key executives will be subject to specific performance goals that reflect the successful execution of Antibe’s business plan, including our monetization strategy. All RSUs are subject to time-based vesting; one third (1/3) of the RSUs granted will vest on each of the first, second and third anniversaries of today’s date. In addition, we have granted BND Projects Inc. 66,000 options for investor relations services. Each option has an exercise price of $4.00, vests quarterly starting on the date of the grant, and will expire January 11, 2024.

Filing Date	Transaction Date	Insider Name	Ownership Type	Securities	Nature of transaction	Volume or Value	Price
Jan 14/23	Jan 11/23	McNealey, Jennifer	Direct Ownership	Common Shares	57 - Exercise of rights	11,667	$0.590
Jan 14/23	Jan 11/23	McNealey, Jennifer	Direct Ownership	Restricted Share Units	57 - Exercise of rights	-11,667	$0.590
Jan 14/23	Jan 11/23	Hoffman, Robert	Direct Ownership	Common Shares	57 - Exercise of rights	11,667	$0.590
Jan 14/23	Jan 11/23	Hoffman, Robert	Direct Ownership	Restricted Share Units	57 - Exercise of rights	-11,667	$0.590
Jan 14/23	Jan 11/23	Wu, Yung Cheng	Direct Ownership	Common Shares	57 - Exercise of rights	13,333	$0.590
Jan 14/23	Jan 11/23	Wu, Yung Cheng	Direct Ownership	Restricted Share Units	57 - Exercise of rights	-13,333	$0.590
Jan 14/23	Jan 11/23	Flower, Roderick John	Direct Ownership	Common Shares	57 - Exercise of rights	13,333	$0.590
Jan 14/23	Jan 11/23	Flower, Roderick John	Direct Ownership	Restricted Share Units	57 - Exercise of rights	-13,333	$0.590
Jan 14/23	Jan 11/23	Stauffer, Joseph	Direct Ownership	Common Shares	57 - Exercise of rights	11,667	$0.590
Jan 14/23	Jan 11/23	Stauffer, Joseph	Direct Ownership	Restricted Share Units	57 - Exercise of rights	-11,667	$0.590